Complete Guide
Tesamorelin: A Complete Guide to Mechanism, Dosing, and Protocols
Published by Peptara Labs · Updated · How we research and check our pages
Tesamorelin is a growth-hormone-releasing hormone analog with an FDA-approved track record for reducing visceral abdominal fat, the deep belly fat tied to metabolic risk that is hard to target any other way.
This guide covers the mechanism, the clinical grounding, the dose the pivotal trial and the FDA label describe with the vial math beside it, side effects as the trial reported them, what has been studied in combination, contraindications, and storage.
Section 1
How does tesamorelin work?
Tesamorelin is an analog of growth-hormone-releasing hormone (GHRH). It prompts the pituitary to release growth hormone in a natural pattern, which in turn influences fat metabolism. Its clinical claim to fame is a specific effect: reducing visceral adipose tissue.
GHRH analog
Rather than injecting growth hormone, Tesamorelin stimulates your own pituitary to release it in a pulsatile way. This is a gentler approach than direct growth-hormone administration and preserves the body's natural rhythm.
Visceral fat targeting
Visceral fat is the deep abdominal fat around the organs, distinct from the subcutaneous fat you can pinch, and it is more strongly linked to metabolic risk. Tesamorelin was studied and approved specifically for reducing this kind of fat, which is unusual and is the main reason people choose it.
Sleep and recovery
Because it works on the growth-hormone axis, many users also report better sleep, the same secondary benefit seen with other growth-hormone secretagogues.
Section 2
Clinical Grounding
Tesamorelin stands out from most research peptides because it has an FDA-approved history. It was approved as Egrifta for reducing excess visceral abdominal fat in a specific patient population, supported by registered clinical trials. That regulatory history gives it stronger clinical grounding than compounds that rely only on preclinical or anecdotal data.
The honest distinction: Peptara supplies research-grade Tesamorelin for research use, which is separate from the approved branded finished pharmaceutical. The molecule has clinical backing; our product is the research-grade form.
For visceral fat specifically, that combination of a clinically studied mechanism and a clear target is what makes Tesamorelin a considered choice rather than a speculative one.
Section 3
Doses as studied: the pivotal trial and the FDA label
The pivotal phase 3 trial gave 2 mg of tesamorelin by daily subcutaneous injection, against placebo, for 26 weeks to 412 adults with HIV and excess abdominal fat (Falutz et al., 2007; doi:10.1056/NEJMoa072375; PMID 18057338). The original FDA label for the brand drug Egrifta describes the same 2 mg once daily.
| Source | Population | Dose reported | Route and frequency | Reported outcome |
|---|---|---|---|---|
| Falutz et al., 2007 (NEJM, phase 3) | Adults with HIV and excess abdominal fat (n=412) | 2 mg | Subcutaneous, once daily, 26 weeks | Visceral fat down 15.2% against a 5.0% rise on placebo; IGF-I up 81.0% |
| FDA Egrifta label | Adults with HIV-associated lipodystrophy | 2 mg | Subcutaneous, once daily | Approved to reduce excess abdominal fat |
These figures describe what researchers used and what the regulator approved for one indication. They are not a dose for anyone reading this, and a later single-vial formulation (Egrifta SV) carries its own separately approved dosing on its own label. The tesamorelin dosage page covers the trial and the label in more detail.
Vial math for a 20mg vial
A 20mg vial mixed with 2ml of bacteriostatic water holds 10mg per ml. On a U-100 insulin syringe 1ml is 100 units, so each unit holds 0.1mg at that strength. That arithmetic reads a label; it is not a dose.
Always measure in units on an insulin syringe, never in mL by eye. See the reconstitution guide for the calculator, and the tesamorelin price per vial for what a vial costs.
Section 4
How the trial gave it
In the pivotal trial, tesamorelin was a daily subcutaneous injection for 26 weeks (Falutz et al., 2007). The trial abstract does not set a time of day, and neither does this page.
Its half-life is short, roughly 26 to 38 minutes in the pharmacokinetic data on the FDA label, which the tesamorelin half-life page explains.
Timing, route and schedule are decisions for a licensed clinician. Nothing in this section is an instruction.
Section 5
What are the side effects of tesamorelin?
Commonly reported
- Injection-site reactions: redness or irritation, usually mild.
- Joint aches or fluid retention: related to growth-hormone activity.
- Blood-sugar changes: growth hormone influences glucose, although the pivotal trial found no significant difference in glycemic measures against placebo over 26 weeks (Falutz et al., 2007).
The honest framing on safety
In the pivotal trial, adverse events did not differ significantly between tesamorelin and placebo, although more people on tesamorelin withdrew because of an adverse event (Falutz et al., 2007). That is a clinical safety record from its approved use, which is more than most research peptides can claim. Even so, growth-hormone-axis effects on glucose and fluid mean people with diabetes or related conditions should consult a physician. People with active cancer or certain pituitary conditions should not use it.
Section 6
Stacking: what has and has not been studied
No published trial has tested tesamorelin together with another peptide, so this section describes the pairings people ask about rather than recommending one.
Tesamorelin and CJC-1295 / Ipamorelin
Tesamorelin and CJC-1295 are both analogs of growth-hormone-releasing hormone (Falutz et al., 2007; Teichman et al., 2006), so they act on the same receptor. No study has tested them together, and combining two compounds on the same axis is outside anything the research covers.
Section 7
Contraindications and Cautions
- Active cancer or certain pituitary conditions: do not use
- Diabetes or blood-sugar disorders: monitor and consult your physician, given growth-hormone effects on glucose
- Pregnancy or breastfeeding: avoid
- Any serious medical condition or prescription regimen: consult your physician before starting
Peptara supplies research-grade Tesamorelin for research use, distinct from the approved pharmaceutical. Treat any significant metabolic decision as one for your physician.
Section 8
Common Mistakes to Avoid
- Expecting fast visible results. The pivotal trial measured visceral fat after 26 weeks (Falutz et al., 2007), in adults with HIV and excess abdominal fat, so its result is not a short-term or personal timeline.
- Ignoring blood sugar. Growth hormone affects glucose. Any blood-sugar concern belongs with a physician before anything else.
- Measuring in mL by eye. Use an insulin syringe and count units. Eyeballing a fraction of a mL is how large measuring errors happen.
- Skipping diet and training. Tesamorelin works best alongside nutrition and activity, not instead of them.
- Reconstitution errors. The standard technique uses bacteriostatic water added down the side of the vial, gentle swirling rather than shaking, and refrigeration after mixing.
Section 9
How do you store and reconstitute tesamorelin?
The lyophilized vial is stable at room temperature before reconstitution. Avoid direct sunlight and heat. For longer storage, refrigerate. Do not freeze the lyophilized powder.
Once reconstituted with bacteriostatic water, store refrigerated at 2-8 degrees C and use within about 30 days. Inspect before each draw: the solution should be clear. Discard if cloudy or discolored.
- The vial top is wiped with an alcohol swab.
- 2ml of bacteriostatic water is drawn into a syringe.
- The standard technique adds the BAC water slowly down the inside wall of the vial, not directly onto the powder.
- The vial is swirled gently, not shaken.
- The powder is left to dissolve fully, and the solution should be clear.
See the Peptara reconstitution guide for an interactive calculator and walkthrough.
Section 10
Frequently Asked Questions
Is Tesamorelin FDA-approved?
Tesamorelin has an FDA-approved track record. It was approved under the brand name Egrifta to reduce excess visceral abdominal fat in a specific patient population, and it has been studied in registered clinical trials. That gives it more clinical grounding than many research peptides. Peptara supplies research-grade Tesamorelin, which is for research use and distinct from the approved branded pharmaceutical.
What makes Tesamorelin different from other fat-loss peptides?
Its specific, clinically studied effect is reducing visceral adipose tissue, the deep abdominal fat that wraps around organs and is tied to metabolic risk. Unlike subcutaneous fat you can pinch, visceral fat is hard to target, which is what makes Tesamorelin distinctive. It works by stimulating your own growth-hormone release rather than suppressing appetite the way GLP-1 peptides do.
How long until I see results?
The pivotal trial measured visceral fat on CT after 26 weeks of daily 2 mg injections and reported a 15.2% decrease, against a 5.0% increase with placebo (Falutz et al., 2007). That is a trial average in adults with HIV and excess abdominal fat, not a timeline for anyone else.
Is Peptara Tesamorelin real?
Every vial comes with a third-party Certificate of Analysis confirming 98%+ purity. We source from verified manufacturers and provide lab documentation on request. Message us on WhatsApp before ordering if you want to see a COA first.
How long does one Tesamorelin vial last?
The vial holds 20mg of Tesamorelin. Reconstituted with 2ml of bacteriostatic water that is 10mg per ml, so any amount converts straight into syringe units. How long it lasts depends entirely on the amount and the frequency, and this site does not work out how many vials a reader needs, because that would require picking a dose. The dose the pivotal trial and the FDA label describe is set out in the doses-as-studied section above.
Do I need to refrigerate Tesamorelin?
The lyophilized vial is stable at room temperature before reconstitution. Once reconstituted with bacteriostatic water, store it in the refrigerator (2-8 degrees C) and use within about 30 days. Storage instructions come with every order.
References
Peer-reviewed sources
- Falutz J, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. doi.org/10.1056/NEJMoa072375
- Teichman SL, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. doi.org/10.1210/jc.2005-1536
Tesamorelin has FDA-approved clinical history for visceral fat reduction. Peptara supplies research-grade Tesamorelin, distinct from the branded product. This guide summarizes published research. It is not medical advice and not a plan for anyone to follow, and any decision about a research compound belongs with a qualified physician.
Order Tesamorelin from Peptara Labs
Tesamorelin orders include a 60-day money back guarantee: send any vial to an independent lab within 60 days of delivery and if it does not test as stated, you are refunded. COA on request, and order support on WhatsApp.
Order TesamorelinSame-day HCMC delivery · 1-3 days nationwide in Vietnam · Free shipping